FDA

152498601

Pain Therapeutics and Durect Stung by Pfizer Move

Pain Therapeutics Inc. (NASDAQ: PTIE) shares dropped significantly in Monday’s trading on news that Pfizer Inc. (NYSE: PFE) had discontinued its agreement to develop and commercialize Pain’s Remoxy extended release ...
Read Full Story »
fda_logo

Sarepta Faces Major Hurdle, and Not From Ebola

In non-Ebola related news, Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot. The stock ...
Read Full Story »
fda_logo

Alcobra Loses Focus in ADHD Trial for FDA Approval

Cognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD), are prevalent within the United States and affect 5% of children. Around half of these children will continue to have ADHD as ...
Read Full Story »
DNA

Chimerix Wants Its Piece of the Ebola Pie

Chimerix Inc. (NASDAQ: CMRX) has become the latest company to get an Ebola announcement out. With scares rising in America after last week's disclosure of a confirmed Ebola case in Dallas, ...
Read Full Story »
biotech

What Else Is Under the Hood for Catalyst Pharma?

Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. In the ...
Read Full Story »
Pills

Will Analysts Start Following Alimera After Its FDA Approval?

Alimera Sciences Inc. (NASDAQ: ALIM) traded up big on Monday on news that the company received U.S. Food and Drug Administration (FDA) approval for its drug Iluvien. The company stated ...
Read Full Story »
152498601

Flexion Therapeutics Stumbles on Clinical Hold

In the after-hours on Wednesday, Flexion Therapeutics Inc. (NASDAQ: FLXN) made a hard fall on the news of a clinical hold. Usually clinical holds result in some serious fall out ...
Read Full Story »
research

NPS Pharma Enters Cautionary Phase of the FDA Approval Process

NPS Pharmaceuticals Inc. (NASDAQ: NPSP) is trading lower on what sounded like good news. The problem is that headlines often do not reveal the underlying story. After its shares were ...
Read Full Story »
145922793

Does New Data Make or Break NPS Pharmaceuticals?

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is up huge in regular trading on Wednesday, due to positive preliminary results of a clinical trial. The FDA has posted the briefing materials prior to ...
Read Full Story »
research

Huntington’s Disease Orphan Drug Designation Could Rescue Prana

Prana Biotechnology Ltd. (NASDAQ: PRAN) saw its shares surge on Friday. This movement is on the heels of the U.S. Food and Drug Administration (FDA) granting an orphan drug designation to ...
Read Full Story »
DNA

What This Skin Cancer Drug Approval Really Means to Merck

Merck & Co. Inc. (NYSE: MRK) has received approval from the FDA to bring its new drug to market. The drug is called Keytruda and it is designed to treat ...
Read Full Story »
health care

ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary ...
Read Full Story »
186171981

Can Tekmira Make Much Money From Its Ebola Treatment?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has made a name for itself pioneering new experimental treatments in the wake of the most recent Ebola scare. Ebola is considered one of the deadliest ...
Read Full Story »
biotech

Should Investors Really Be Chasing Potential Ebola Treatments?

The world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been ...
Read Full Story »
biotech

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The ...
Read Full Story »